Supreme Court Strengthens Generic Liability Shield; FDA Reg Change Could Create Opening
This article was originally published in The Pink Sheet Daily
Executive Summary
The high court rules 5-4 that generic drug makers cannot be sued for alleged design defects based on the adequacy of a drug’s label warnings; FDA continues to discuss revising its regulations to allow generic companies to change their labeling.
You may also be interested in...
Court Wants Defense Of Acetaminophen Pregnancy Warning, US FDA Provides Research Review
Review makes clear FDA’s thinking on safety acetaminophen use during pregnancy, but likely won’t sway federal judge from her conclusion that a warning about risks of in utero exposure could be added to drug containing the ingredient and available under an OTC monograph without violating FDA regulations.
Court Rejects Preemption, Asks FDA To Defend Pregnancy Label Warning For OTC Acetaminophen
Ruling on pre-trial motion in complaint against a Kenvue business in District Court for Southern New York is first in litigation alleging damages from using OTC monograph drug to find against federal preemption of state consumer protection laws and similar regulations.
Brand-Name Drug Makers' Duty To Warn Extends After Product Sale To Another Company
California Supreme Court finds Novartis liable for alleged injuries from use of a generic version of Brethine even though they occurred six years after Novartis transferred the NDA; dissenting opinion says this will expose companies to "liability in perpetuity."